T1	Participants 89 138	patients with localized high-risk prostate cancer
T2	Participants 216 289	localized high-risk prostate cancers (PCa) and some intermediate-risk PCa
T3	Participants 804 841	patients with localized high-risk PCa
T4	Participants 2021 2043	ocalized high-risk PCa
